|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6395494B1
(en)
|
1993-05-13 |
2002-05-28 |
Neorx Corporation |
Method to determine TGF-β
|
|
US6251920B1
(en)
|
1993-05-13 |
2001-06-26 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
|
US6306421B1
(en)
|
1992-09-25 |
2001-10-23 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6277410B1
(en)
*
|
1992-10-08 |
2001-08-21 |
Supratek Pharma Inc. |
Copolymer compositions for oral delivery
|
|
FR2697752B1
(fr)
*
|
1992-11-10 |
1995-04-14 |
Rhone Poulenc Rorer Sa |
Compositions antitumorales contenant des dérivés du taxane.
|
|
US5298262A
(en)
*
|
1992-12-04 |
1994-03-29 |
Sterling Winthrop Inc. |
Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
|
|
US5346702A
(en)
*
|
1992-12-04 |
1994-09-13 |
Sterling Winthrop Inc. |
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
|
|
FR2698871B1
(fr)
|
1992-12-09 |
1995-02-24 |
Rhone Poulenc Rorer Sa |
Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
|
|
US6663881B2
(en)
|
1993-01-28 |
2003-12-16 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5525559A
(en)
*
|
1993-02-13 |
1996-06-11 |
Tioxide Specialties Limited |
Preparation of mixed powders
|
|
US6753006B1
(en)
*
|
1993-02-22 |
2004-06-22 |
American Bioscience, Inc. |
Paclitaxel-containing formulations
|
|
US6749868B1
(en)
|
1993-02-22 |
2004-06-15 |
American Bioscience, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
|
US20030068362A1
(en)
*
|
1993-02-22 |
2003-04-10 |
American Bioscience, Inc. |
Methods and formulations for the delivery of pharmacologically active agents
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
US5439686A
(en)
*
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
|
US6096331A
(en)
|
1993-02-22 |
2000-08-01 |
Vivorx Pharmaceuticals, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
US20030133955A1
(en)
*
|
1993-02-22 |
2003-07-17 |
American Bioscience, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
US20070117862A1
(en)
*
|
1993-02-22 |
2007-05-24 |
Desai Neil P |
Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US8143283B1
(en)
*
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US5830436A
(en)
*
|
1993-03-30 |
1998-11-03 |
Duke University |
Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
|
|
US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
|
US5840277A
(en)
*
|
1993-03-30 |
1998-11-24 |
Charlotte Hospital Authority |
Treatment of chronic pulmonary inflammation
|
|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
|
US6441026B1
(en)
|
1993-11-08 |
2002-08-27 |
Aventis Pharma S.A. |
Antitumor compositions containing taxane derivatives
|
|
US5534270A
(en)
*
|
1995-02-09 |
1996-07-09 |
Nanosystems Llc |
Method of preparing stable drug nanoparticles
|
|
US5573783A
(en)
*
|
1995-02-13 |
1996-11-12 |
Nano Systems L.L.C. |
Redispersible nanoparticulate film matrices with protective overcoats
|
|
US5510118A
(en)
*
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
|
CA2213638C
(en)
*
|
1995-02-24 |
2004-05-04 |
Nanosystems L.L.C. |
Aerosols containing nanoparticle dispersions
|
|
DE19512484A1
(de)
*
|
1995-04-04 |
1996-10-17 |
Bayer Ag |
Kohlenhydratmodifizierte Cytostatika
|
|
US5731325A
(en)
*
|
1995-06-06 |
1998-03-24 |
Andrulis Pharmaceuticals Corp. |
Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
|
|
US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
WO1997004756A2
(en)
*
|
1995-07-26 |
1997-02-13 |
Nanosystems L.L.C. |
Methacrylate backbone surfactants in nanoparticulate formulations
|
|
US6391338B1
(en)
|
1995-09-07 |
2002-05-21 |
Biovail Technologies Ltd. |
System for rendering substantially non-dissoluble bio-affecting agents bio-available
|
|
US5834025A
(en)
*
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
|
US6346510B1
(en)
*
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
|
US5955509A
(en)
*
|
1996-05-01 |
1999-09-21 |
Board Of Regents, The University Of Texas System |
pH dependent polymer micelles
|
|
DE69734060T2
(de)
*
|
1996-05-24 |
2006-06-29 |
Angiotech Pharmaceuticals, Inc., Vancouver |
Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
|
|
US20030195846A1
(en)
*
|
1996-06-05 |
2003-10-16 |
David Felger |
Method of billing a purchase made over a computer network
|
|
US6491903B1
(en)
|
1996-06-27 |
2002-12-10 |
Washington University |
Particles comprising amphiphilic copolymers
|
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
|
US20070092563A1
(en)
*
|
1996-10-01 |
2007-04-26 |
Abraxis Bioscience, Inc. |
Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
DE69734290T2
(de)
*
|
1996-11-05 |
2006-07-06 |
The Children's Medical Center Corp., Boston |
Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
|
|
US6515016B2
(en)
|
1996-12-02 |
2003-02-04 |
Angiotech Pharmaceuticals, Inc. |
Composition and methods of paclitaxel for treating psoriasis
|
|
FR2759293B1
(fr)
*
|
1997-02-11 |
1999-04-30 |
Ethypharm Lab Prod Ethiques |
Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
|
|
US6045829A
(en)
|
1997-02-13 |
2000-04-04 |
Elan Pharma International Limited |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
|
|
WO1998035666A1
(en)
*
|
1997-02-13 |
1998-08-20 |
Nanosystems Llc |
Formulations of nanoparticle naproxen tablets
|
|
EP1014990B1
(en)
*
|
1997-03-07 |
2006-09-06 |
Sanofi-Aventis U.S. LLC |
Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
|
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
|
AU6853498A
(en)
*
|
1997-04-22 |
1998-11-13 |
Nippon Kayaku Kabushiki Kaisha |
Flutamide preparations and method for manufacturing the same
|
|
US20020039594A1
(en)
*
|
1997-05-13 |
2002-04-04 |
Evan C. Unger |
Solid porous matrices and methods of making and using the same
|
|
US6051558A
(en)
*
|
1997-05-28 |
2000-04-18 |
Southern Biosystems, Inc. |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US20060025328A1
(en)
*
|
1997-05-28 |
2006-02-02 |
Burns Patrick J |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
PT1023050E
(pt)
*
|
1997-06-27 |
2013-12-04 |
Abraxis Bioscience Llc |
Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
|
|
US20030199425A1
(en)
*
|
1997-06-27 |
2003-10-23 |
Desai Neil P. |
Compositions and methods for treatment of hyperplasia
|
|
US8853260B2
(en)
*
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
UA72189C2
(ru)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Водные суспензии субмикронной формы эфиров 9-гидроксирисперидона жирных кислот
|
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
|
US6673828B1
(en)
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
|
JP2002516267A
(ja)
|
1998-05-29 |
2002-06-04 |
アールティーピー・ファーマ・インコーポレーテッド |
熱的に保護された微粒子組成物及びその最終蒸気滅菌
|
|
US6153225A
(en)
*
|
1998-08-13 |
2000-11-28 |
Elan Pharma International Limited |
Injectable formulations of nanoparticulate naproxen
|
|
EP1105096B1
(en)
|
1998-08-19 |
2003-10-29 |
Skyepharma Canada Inc. |
Injectable aqueous dispersions of propofol
|
|
US6350786B1
(en)
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
|
EP2266542A3
(en)
*
|
1998-10-01 |
2013-07-31 |
Elan Pharma International Limited |
Controlled release nanoparticulate compositions
|
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
|
CA2348871C
(en)
*
|
1998-11-02 |
2009-04-14 |
John G. Devane |
Multiparticulate modified release composition
|
|
US20070160675A1
(en)
*
|
1998-11-02 |
2007-07-12 |
Elan Corporation, Plc |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
|
US20040141925A1
(en)
*
|
1998-11-12 |
2004-07-22 |
Elan Pharma International Ltd. |
Novel triamcinolone compositions
|
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
|
US6969529B2
(en)
*
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
|
US6984404B1
(en)
|
1998-11-18 |
2006-01-10 |
University Of Florida Research Foundation, Inc. |
Methods for preparing coated drug particles and pharmaceutical formulations thereof
|
|
US7939105B2
(en)
|
1998-11-20 |
2011-05-10 |
Jagotec Ag |
Process for preparing a rapidly dispersing solid drug dosage form
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
US6395511B1
(en)
*
|
1998-11-27 |
2002-05-28 |
Darwin Discovery, Ltd. |
Nucleic acids encoding a novel family of TGF-β binding proteins from humans
|
|
DE19856432A1
(de)
|
1998-12-08 |
2000-06-15 |
Basf Ag |
Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
|
|
US6040330A
(en)
*
|
1999-01-08 |
2000-03-21 |
Bionumerik Pharmaceuticals, Inc. |
Pharmaceutical formulations of taxanes
|
|
US6267989B1
(en)
|
1999-03-08 |
2001-07-31 |
Klan Pharma International Ltd. |
Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
|
|
EP1754488A1
(en)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
|
US6444223B1
(en)
|
1999-05-28 |
2002-09-03 |
Alkermes Controlled Therapeutics, Inc. |
Method of producing submicron particles of a labile agent and use thereof
|
|
US6406745B1
(en)
*
|
1999-06-07 |
2002-06-18 |
Nanosphere, Inc. |
Methods for coating particles and particles produced thereby
|
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
|
US20090104273A1
(en)
*
|
1999-06-22 |
2009-04-23 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
|
US6656504B1
(en)
*
|
1999-09-09 |
2003-12-02 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
|
|
CA2383233C
(en)
*
|
1999-09-21 |
2010-06-08 |
Rtp Pharma Inc. |
Surface modified particulate compositions of biologically active substances
|
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
|
JP2004501068A
(ja)
*
|
2000-01-31 |
2004-01-15 |
コラボレイティヴ・テクノロジーズ・インコーポレーテッド |
界面活性剤を含まない局所用組成物、及びその迅速な調製方法
|
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
|
PT1650221E
(pt)
|
2000-02-23 |
2012-09-05 |
Glaxosmithkline Biolog Sa |
Novos compostos
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
|
AU6867801A
(en)
|
2000-06-20 |
2002-01-02 |
Corixa Corp |
Fusion proteins of mycobacterium tuberculosis
|
|
JP2004513615A
(ja)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
肺癌の治療および診断のための組成物および方法
|
|
US20030224058A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
|
RU2179170C1
(ru)
*
|
2000-10-05 |
2002-02-10 |
Жукова Инна Борисовна |
Средство, ингибирующее пролиферацию лимфоцитов
|
|
MXPA03003401A
(es)
*
|
2000-10-16 |
2004-06-30 |
Neopharm Inc |
Formulacion liposomica de mitoxantrona.
|
|
RU2191006C2
(ru)
*
|
2000-10-27 |
2002-10-20 |
Российский онкологический научный центр им. Н.Н.Блохина РАМН |
Способ лечения диссеминированной формы остеогенной саркомы
|
|
ATE374609T1
(de)
*
|
2000-11-30 |
2007-10-15 |
Childrens Medical Center |
Synthese von 4-aminothalidomid enantiomeren
|
|
EP1404359A2
(en)
*
|
2000-12-07 |
2004-04-07 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
|
US6607784B2
(en)
*
|
2000-12-22 |
2003-08-19 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
|
US6623761B2
(en)
|
2000-12-22 |
2003-09-23 |
Hassan Emadeldin M. |
Method of making nanoparticles of substantially water insoluble materials
|
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
|
RS20100015A
(sr)
*
|
2001-01-26 |
2010-12-31 |
Schering Corporation |
Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
|
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
|
HU230435B1
(hu)
|
2001-01-26 |
2016-06-28 |
Merck Sharp & Dohme Corp |
Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
|
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
US6497896B2
(en)
|
2001-02-12 |
2002-12-24 |
Supergen, Inc. |
Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
|
|
US6509027B2
(en)
|
2001-02-12 |
2003-01-21 |
Supergen, Inc. |
Injectable pharmaceutical composition comprising coated particles of camptothecin
|
|
US20020150615A1
(en)
*
|
2001-02-12 |
2002-10-17 |
Howard Sands |
Injectable pharmaceutical composition comprising microdroplets of a camptothecin
|
|
EP1372394A1
(en)
|
2001-04-03 |
2004-01-02 |
Schering Corporation |
Antifungal composition with enhanced bioavailability
|
|
US6613083B2
(en)
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
|
DE60203506T2
(de)
*
|
2001-06-22 |
2006-02-16 |
Marie Lindner |
Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
|
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
|
US20030095928A1
(en)
*
|
2001-09-19 |
2003-05-22 |
Elan Pharma International Limited |
Nanoparticulate insulin
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
CA2460340C
(en)
|
2001-09-21 |
2011-02-15 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
|
|
WO2003026611A2
(en)
*
|
2001-09-26 |
2003-04-03 |
Baxter International Inc. |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
|
EP1443912B1
(en)
*
|
2001-10-12 |
2007-08-29 |
Elan Pharma International Limited |
Compositions having a combination of immediate release and controlled release characteristics
|
|
CA2461556A1
(en)
*
|
2001-10-15 |
2003-04-24 |
Crititech, Inc. |
Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
|
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
|
EP1450863A4
(en)
*
|
2001-11-07 |
2009-01-07 |
Imcor Pharmaceutical Company |
PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS
|
|
RU2191581C1
(ru)
*
|
2001-11-16 |
2002-10-27 |
Нестерук Владимир Викторович |
Способ получения раствора фторурацила
|
|
AU2001298077A1
(en)
*
|
2001-12-06 |
2003-06-17 |
Ranbaxy Laboratories Limited |
Isotretinoin nanoparticulate compositions
|
|
UA76810C2
(ru)
*
|
2001-12-10 |
2006-09-15 |
Мерк Енд Ко., Інк. |
Фармацевтическая композиция антагониста рецептора тахикинина в форме наночастиц
|
|
CA2476755C
(en)
|
2001-12-17 |
2014-08-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
|
JP2005513145A
(ja)
*
|
2001-12-21 |
2005-05-12 |
セラター テクノロジーズ インコーポレイテッド |
改変されたポリマー脂質送達ビヒクル
|
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
|
CA2475092C
(en)
*
|
2002-02-04 |
2012-05-01 |
Christian F. Wertz |
Nanoparticulate compositions having lysozyme as a surface stabilizer
|
|
US20040101566A1
(en)
*
|
2002-02-04 |
2004-05-27 |
Elan Pharma International Limited |
Novel benzoyl peroxide compositions
|
|
US20030164219A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Joerg Brahm |
Headliner/duct assembly and welding process therefor
|
|
US20040009939A1
(en)
*
|
2002-03-05 |
2004-01-15 |
Board Of Regent, The University Of Texas System |
Methods of enhancing immune induction involving MDA-7
|
|
WO2003080023A2
(en)
*
|
2002-03-20 |
2003-10-02 |
Elan Pharma International Limited |
Fast dissolving dosage forms having reduced friability
|
|
EP1800666A1
(en)
*
|
2002-03-20 |
2007-06-27 |
Elan Pharma International Limited |
Nanoparticulate compositions of angiogenesis inhibitors
|
|
CA2479665C
(en)
*
|
2002-03-20 |
2011-08-30 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
|
US20040076586A1
(en)
*
|
2002-03-28 |
2004-04-22 |
Reinhard Koening |
Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
|
|
AU2003221841A1
(en)
|
2002-04-03 |
2003-10-27 |
Celltech R And D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
|
US7332469B2
(en)
|
2002-04-05 |
2008-02-19 |
Board Of Regents The University Of Texas System |
Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
|
|
US7101576B2
(en)
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
|
EP1494649B1
(en)
|
2002-04-12 |
2012-01-04 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
|
US9101540B2
(en)
*
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
|
EP1503737B1
(en)
*
|
2002-05-06 |
2009-01-07 |
Elan Pharma International Limited |
Nanoparticulate nystatin formulations
|
|
EP1509256B1
(en)
*
|
2002-05-24 |
2009-07-22 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
|
US8313760B2
(en)
*
|
2002-05-24 |
2012-11-20 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
|
KR100530369B1
(ko)
*
|
2002-05-27 |
2005-11-22 |
이영환 |
항암물질에 나노입자를 결합시킨 주사 제형의 약물 시스템
|
|
EP1511467A1
(en)
*
|
2002-06-10 |
2005-03-09 |
Elan Pharma International Limited |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
|
CA2488499C
(en)
*
|
2002-06-10 |
2013-03-19 |
Elan Pharma International Ltd. |
Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
|
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
|
CA2492488A1
(en)
*
|
2002-07-16 |
2004-01-22 |
Elan Pharma International, Ltd. |
Liquid dosage compositions of stable nanoparticulate active agents
|
|
PT1530457E
(pt)
|
2002-08-12 |
2009-11-06 |
Bend Res Inc |
Composições farmacêuticas de fármacos na forma semi-ordenada e de polímeros
|
|
KR20130012595A
(ko)
|
2002-08-12 |
2013-02-04 |
제네렉스, 인코포레이티드 |
폭스바이러스 및 암과 관련된 방법 및 조성물
|
|
ATE487470T1
(de)
*
|
2002-09-11 |
2010-11-15 |
Elan Pharma Int Ltd |
Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
|
|
JP2006501936A
(ja)
*
|
2002-10-04 |
2006-01-19 |
エラン ファーマ インターナショナル，リミティド |
固体ナノ粒子活性薬剤のガンマ線照射
|
|
US6966990B2
(en)
|
2002-10-11 |
2005-11-22 |
Ferro Corporation |
Composite particles and method for preparing
|
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
|
MXPA05004811A
(es)
|
2002-11-06 |
2005-07-22 |
Schering Corp |
Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
|
|
ATE514418T1
(de)
*
|
2002-11-12 |
2011-07-15 |
Elan Pharma Int Ltd |
Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
|
|
EP1935407A1
(en)
*
|
2002-12-03 |
2008-06-25 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
|
EP2359859A1
(en)
|
2002-12-09 |
2011-08-24 |
Abraxis BioScience, LLC |
Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
|
|
CN101797221B
(zh)
|
2002-12-13 |
2013-06-12 |
杜雷科特公司 |
包含高粘度液体载体材料的口服递药系统
|
|
US20040173696A1
(en)
*
|
2002-12-17 |
2004-09-09 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
EP1589934B1
(en)
|
2003-01-06 |
2015-09-23 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
CA2513064C
(en)
*
|
2003-01-31 |
2009-11-10 |
Elan Pharma International, Ltd. |
Nanoparticulate topiramate formulations
|
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
|
US7083748B2
(en)
*
|
2003-02-07 |
2006-08-01 |
Ferro Corporation |
Method and apparatus for continuous particle production using supercritical fluid
|
|
US6931888B2
(en)
|
2003-02-07 |
2005-08-23 |
Ferro Corporation |
Lyophilization method and apparatus for producing particles
|
|
CN1759122B
(zh)
*
|
2003-03-03 |
2012-06-13 |
得克萨斯州大学系统董事会 |
包含mda-7的组合物和方法
|
|
US8512727B2
(en)
*
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
|
CA2517571C
(en)
|
2003-03-07 |
2011-07-05 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
MXPA05009501A
(es)
*
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
|
US7459442B2
(en)
*
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
MXPA05009502A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
|
EP1608359A4
(en)
*
|
2003-04-03 |
2011-08-17 |
Jessie L-S Au |
DRUG-LOADING PARTICLES TARGETING TUMORS
|
|
US20060008531A1
(en)
*
|
2003-05-08 |
2006-01-12 |
Ferro Corporation |
Method for producing solid-lipid composite drug particles
|
|
DE10323597A1
(de)
*
|
2003-05-19 |
2004-12-09 |
Aesculap Ag & Co. Kg |
Medizintechnisches Produkt, Verfahren zu seiner Herstellung und Verwendung
|
|
WO2004103346A1
(en)
*
|
2003-05-20 |
2004-12-02 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of acitretin
|
|
CA2523035C
(en)
*
|
2003-05-22 |
2011-04-26 |
Elan Pharma International Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
|
EA015166B1
(ru)
|
2003-06-16 |
2011-06-30 |
Ю-Си-Би Мэньюфэкчуринг, Инк. |
Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
|
|
US20050106310A1
(en)
*
|
2003-07-02 |
2005-05-19 |
Green John H. |
Designed particle agglomeration
|
|
US20050064595A1
(en)
|
2003-07-16 |
2005-03-24 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
EP1651189B1
(en)
*
|
2003-08-08 |
2008-12-03 |
Elan Pharma International Limited |
Novel metaxalone compositions
|
|
US7419996B2
(en)
*
|
2003-08-13 |
2008-09-02 |
The University Of Houston |
Parenteral and oral formulations of benzimidazoles
|
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
|
EP1684580A2
(en)
|
2003-10-22 |
2006-08-02 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in tissues and organs
|
|
CA2544627A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Elan Pharma International Ltd. |
Nanoparticulate compositions having a peptide as a surface stabilizer
|
|
US20050152941A1
(en)
*
|
2003-11-20 |
2005-07-14 |
Angiotech International Ag |
Soft tissue implants and anti-scarring agents
|
|
WO2005051511A1
(ja)
*
|
2003-11-28 |
2005-06-09 |
Mitsubishi Chemical Corporation |
有機化合物微粒子の製造方法
|
|
CA2548220A1
(en)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Use of mda-7 to inhibit infection by pathogenic organisms
|
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
|
DE102004011776A1
(de)
*
|
2004-03-09 |
2005-11-03 |
Lts Lohmann Therapie-Systeme Ag |
Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen
|
|
EP1730516A1
(en)
*
|
2004-03-30 |
2006-12-13 |
Pfizer Products Incorporated |
Method and device for evaluation of pharmaceutical compositions
|
|
US20050220866A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Dr. Reddy's Laboratories Limited |
Novel capsule formulations of etoposide for oral use
|
|
ES2246694B1
(es)
*
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
EP2497831B1
(en)
|
2004-05-25 |
2014-07-16 |
Oregon Health and Science University |
TB vaccination using HCMV-based vaccine vectors
|
|
US7871632B2
(en)
*
|
2004-07-12 |
2011-01-18 |
Adventrx Pharmaceuticals, Inc. |
Compositions for delivering highly water soluble drugs
|
|
JP2008510000A
(ja)
*
|
2004-08-19 |
2008-04-03 |
アルザ・コーポレーシヨン |
制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法
|
|
WO2006028074A1
(ja)
*
|
2004-09-07 |
2006-03-16 |
Mitsubishi Chemical Corporation |
微粒子化された物質の製造方法および微粒子化された物質
|
|
DK2767292T3
(en)
*
|
2004-09-17 |
2016-12-19 |
Durect Corp |
RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
|
|
AU2005290238A1
(en)
|
2004-09-18 |
2006-04-06 |
Department Of Veterans Affairs |
Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
|
|
WO2006034048A2
(en)
|
2004-09-18 |
2006-03-30 |
University Of Maryland, Baltimore |
Therapeutic agents targeting the ncca-atp channel and methods of use thereof
|
|
US20090155331A1
(en)
*
|
2005-11-16 |
2009-06-18 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
|
EA200701065A1
(ru)
*
|
2004-11-16 |
2007-12-28 |
Элан Фарма Интернэшнл Лтд. |
Инъецируемые составы, содержащие нанодисперсный оланзапин
|
|
UA89513C2
(ru)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Стабильная композиция из наночастичек ралоксифена гидрохлорида
|
|
MX2007007342A
(es)
*
|
2004-12-15 |
2007-12-11 |
Elan Pharma Int Ltd |
Formulaciones de tacrolimus nanoparticuladas.
|
|
US20060159767A1
(en)
*
|
2004-12-22 |
2006-07-20 |
Elan Pharma International Limited |
Nanoparticulate bicalutamide formulations
|
|
CN101132770A
(zh)
*
|
2005-01-06 |
2008-02-27 |
伊兰制药国际有限公司 |
纳米微粒坎地沙坦制剂
|
|
WO2006086798A2
(en)
*
|
2005-02-08 |
2006-08-17 |
Board Of Regents, The University Of Texas System |
Compositions and methods involving mda-7 for the treatment of cancer
|
|
MX2007009915A
(es)
|
2005-02-15 |
2007-11-06 |
Elan Pharma Int Ltd |
Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
|
|
CA2598239C
(en)
|
2005-02-18 |
2019-10-29 |
Abraxis Bioscience, Inc. |
Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
|
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
MX2007010394A
(es)
*
|
2005-02-24 |
2008-02-19 |
Elan Pharma Int Ltd |
Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
|
|
AU2005100176A4
(en)
*
|
2005-03-01 |
2005-04-07 |
Gym Tv Pty Ltd |
Garbage bin clip
|
|
EP1855651A4
(en)
*
|
2005-03-03 |
2011-06-15 |
Elan Pharma Int Ltd |
NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
|
|
US20060204588A1
(en)
*
|
2005-03-10 |
2006-09-14 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
|
|
CN101175480A
(zh)
*
|
2005-03-16 |
2008-05-07 |
伊兰制药国际有限公司 |
纳米微粒白三烯受体拮抗剂/皮质类固醇制剂
|
|
EP1868576A2
(en)
*
|
2005-03-17 |
2007-12-26 |
Elan Pharma International Limited |
Injectable compositions of nanoparticulate immunosuppressive compounds
|
|
BRPI0606280A2
(pt)
*
|
2005-03-17 |
2009-06-09 |
Elan Pharma Int Ltd |
composições de bisfosfonato nanoparticulado
|
|
CA2602341A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Elan Pharma International Limited |
Nanoparticulate corticosteroid and antihistamine formulations
|
|
EP2392347A3
(en)
|
2005-03-31 |
2012-01-18 |
GlaxoSmithKline Biologicals S.A. |
Vaccines against chlamydial infection
|
|
EP1871345B1
(en)
*
|
2005-04-12 |
2012-08-01 |
Elan Pharma International Limited |
Nanoparticulate erlotinib formulations
|
|
WO2006110809A2
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
|
MX2007012762A
(es)
*
|
2005-04-12 |
2008-01-14 |
Elan Pharma Int Ltd |
Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
|
|
US8466133B2
(en)
|
2005-04-22 |
2013-06-18 |
University Of Geneva |
Polylactides compositions and uses thereof
|
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
|
EP1877426B1
(en)
|
2005-04-29 |
2012-02-01 |
GlaxoSmithKline Biologicals SA |
Method for preventing or treating m tuberculosis infection
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
US20110064803A1
(en)
*
|
2005-05-10 |
2011-03-17 |
Elan Pharma International Limited. |
Nanoparticulate and controlled release compositions comprising vitamin k2
|
|
JP2008540550A
(ja)
*
|
2005-05-10 |
2008-11-20 |
エラン・ファルマ・インターナショナル・リミテッド |
ビタミンｋ２を含むナノ粒子および制御放出組成物
|
|
US20100028439A1
(en)
*
|
2005-05-23 |
2010-02-04 |
Elan Pharma International Limited |
Nanoparticulate stabilized anti-hypertensive compositions
|
|
AU2006309295B2
(en)
*
|
2005-06-03 |
2012-04-26 |
Elan Pharma International Limited |
Nanoparticulate acetaminophen formulations
|
|
US20070042049A1
(en)
*
|
2005-06-03 |
2007-02-22 |
Elan Pharma International, Limited |
Nanoparticulate benidipine compositions
|
|
ATE459341T1
(de)
*
|
2005-06-03 |
2010-03-15 |
Elan Pharma Int Ltd |
Nanoteilchenförmige imatinib-mesylat- formulierungen
|
|
EP1954253A4
(en)
|
2005-06-08 |
2011-07-27 |
Elan Pharma Int Ltd |
NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
|
|
JP2008543766A
(ja)
*
|
2005-06-09 |
2008-12-04 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子エバスチン製剤
|
|
BRPI0611626A2
(pt)
*
|
2005-06-13 |
2010-09-21 |
Elan Pharma Int Ltd |
formulações da combinação de nanopartìculas de clopidogrel e aspirina
|
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
|
WO2006138202A2
(en)
*
|
2005-06-14 |
2006-12-28 |
Baxter International Inc. |
Pharmaceutical formulations for minimizing drug-drug interactions
|
|
JP2008543862A
(ja)
*
|
2005-06-15 |
2008-12-04 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子アゼルニジピン製剤
|
|
EA200800099A1
(ru)
*
|
2005-06-22 |
2008-06-30 |
Элан Фарма Интернэшнл Лтд. |
Композиции наночастиц мегестрола
|
|
CA2614412A1
(en)
*
|
2005-07-07 |
2007-01-18 |
Elan Pharma International, Limited |
Nanoparticulate clarithromycin formulations
|
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
|
GB0516549D0
(en)
*
|
2005-08-12 |
2005-09-21 |
Sulaiman Brian |
Milling system
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
EP1933857A2
(en)
*
|
2005-09-07 |
2008-06-25 |
Jennerex Biotherapeutics ULC |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
|
JP2009507925A
(ja)
*
|
2005-09-13 |
2009-02-26 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子タダラフィル製剤
|
|
EP1933814A2
(en)
|
2005-09-15 |
2008-06-25 |
Elan Pharma International Limited |
Nanoparticulate aripiprazole formulations
|
|
US20070077309A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Wong Patrick S |
Banded controlled release nanoparticle active agent formulation dosage forms and methods
|
|
BRPI0618661A2
(pt)
*
|
2005-11-15 |
2011-09-06 |
Baxter Int |
composições de inibidores de lipoxigenase
|
|
AU2006318212C1
(en)
|
2005-11-23 |
2012-08-30 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
|
EP1959966B1
(en)
*
|
2005-11-28 |
2020-06-03 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone formulations and methods for the making and use thereof
|
|
CA2631331C
(en)
|
2005-11-28 |
2016-08-09 |
Gtx, Inc. |
Nuclear receptor binding agents
|
|
JP2009522372A
(ja)
|
2006-01-09 |
2009-06-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ワクチンおよび腫瘍免疫療法のためのｔｎｆｒｓｆ、ｔｌｒ、ｎｌｒ、ｒｈｒ、プリン受容体、およびサイトカイン受容体アゴニストの組み合わせ免疫刺激剤
|
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
|
US20080166411A1
(en)
*
|
2006-04-10 |
2008-07-10 |
Pfizer Inc |
Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
|
|
CA2648007A1
(en)
*
|
2006-04-24 |
2007-11-01 |
Bruce Medical Ab |
Polymer-based anti-cancer agents
|
|
US20070264350A1
(en)
*
|
2006-05-15 |
2007-11-15 |
Ebara Corporation |
Water-insoluble medicine
|
|
CN101495096A
(zh)
*
|
2006-05-30 |
2009-07-29 |
伊兰制药国际有限公司 |
纳米微粒泊沙康唑制剂
|
|
TW200820991A
(en)
*
|
2006-07-10 |
2008-05-16 |
Elan Pharma Int Ltd |
Nanoparticulate sorafenib formulations
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
|
US8080645B2
(en)
*
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
|
EP2064229B1
(en)
|
2006-09-15 |
2015-08-12 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
|
WO2008036776A2
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
|
WO2008035229A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Labopharm, Inc. |
Compositions and methods for ph targeted drug delivery
|
|
WO2008070350A2
(en)
|
2006-10-27 |
2008-06-12 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
|
EP2484347A1
(en)
|
2006-11-03 |
2012-08-08 |
Durect Corporation |
Transdermal delivery systems comprising bupivacaine
|
|
EP2094731A2
(en)
*
|
2006-11-10 |
2009-09-02 |
UCB Pharma S.A. |
Anti human sclerostin antibodies
|
|
WO2008061013A2
(en)
*
|
2006-11-10 |
2008-05-22 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
|
EP2097092A4
(en)
|
2006-11-21 |
2010-04-07 |
|
MODULATION OF RHAMM (CD168) FOR THE SELECTIVE DEVELOPMENT OF ADIPOSIS TISSUE
|
|
EP2101735A2
(en)
|
2006-11-28 |
2009-09-23 |
Marinus Pharmaceuticals, Inc. |
Nanoparticulate formulations and methods for the making and use thereof
|
|
WO2008065502A1
(en)
*
|
2006-11-29 |
2008-06-05 |
Pfizer Products Inc. |
Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
|
|
PE20081506A1
(es)
|
2006-12-12 |
2008-12-09 |
Infinity Discovery Inc |
Formulaciones de ansamicina
|
|
WO2008080047A2
(en)
*
|
2006-12-23 |
2008-07-03 |
Baxter International Inc. |
Magnetic separation of fine particles from compositions
|
|
CA2674949A1
(en)
|
2007-01-12 |
2008-07-24 |
J. Marc Simard |
Targeting ncca-atp channel for organ protection following ischemic episode
|
|
CA2677264C
(en)
|
2007-02-02 |
2021-11-30 |
Baylor College Of Medicine |
Compositions and methods for the treatment of metabolic disorders
|
|
US20100092469A1
(en)
|
2007-02-09 |
2010-04-15 |
Simard J Marc |
Antagonists of a non-selective cation channel in neural cells
|
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
|
JP5378350B2
(ja)
*
|
2007-04-04 |
2013-12-25 |
インフェクティアス ディジーズ リサーチ インスティチュート |
結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
|
|
EP3492596A1
(en)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
WO2008125940A2
(en)
*
|
2007-04-17 |
2008-10-23 |
Pfizer Products Inc. |
Nanoparticles comprising non-crystalline drug
|
|
WO2008135855A2
(en)
*
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
|
|
WO2008135852A2
(en)
*
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising nanoparticles and casein
|
|
US8309129B2
(en)
*
|
2007-05-03 |
2012-11-13 |
Bend Research, Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
|
WO2008138755A2
(en)
*
|
2007-05-11 |
2008-11-20 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions for poorly soluble drugs
|
|
US20080293814A1
(en)
*
|
2007-05-22 |
2008-11-27 |
Deepak Tiwari |
Concentrate esmolol
|
|
US8722736B2
(en)
*
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
|
US8426467B2
(en)
*
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
|
WO2008149346A2
(en)
|
2007-06-04 |
2008-12-11 |
Ben Gurion University Of The Negev Research And Development Authority |
Enhanced sensitivity polymerase chain reactions
|
|
EP2162120B1
(en)
*
|
2007-06-04 |
2016-05-04 |
Bend Research, Inc |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
|
WO2008149230A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
|
|
EP2167107B1
(en)
|
2007-06-22 |
2016-12-14 |
University of Maryland, Baltimore |
Inhibitors of ncca-atp channels for therapy
|
|
US20100215747A1
(en)
*
|
2007-07-13 |
2010-08-26 |
Corey Jay Bloom |
Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
|
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
|
EP2772267B1
(en)
|
2007-08-27 |
2016-04-27 |
Longhorn Vaccines and Diagnostics, LLC |
Immunogenic compositions and methods
|
|
US20090130210A1
(en)
*
|
2007-09-11 |
2009-05-21 |
Raheja Praveen |
Pharmaceutical compositions of sirolimus
|
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
|
WO2009085355A2
(en)
|
2007-10-01 |
2009-07-09 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection and transport system and methods of use
|
|
US9233078B2
(en)
*
|
2007-12-06 |
2016-01-12 |
Bend Research, Inc. |
Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
|
|
US9724362B2
(en)
*
|
2007-12-06 |
2017-08-08 |
Bend Research, Inc. |
Pharmaceutical compositions comprising nanoparticles and a resuspending material
|
|
WO2009075782A1
(en)
|
2007-12-06 |
2009-06-18 |
Durect Corporation |
Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
|
|
US20090238867A1
(en)
*
|
2007-12-13 |
2009-09-24 |
Scott Jenkins |
Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
|
|
EP2628486A3
(en)
|
2007-12-14 |
2013-10-30 |
Amgen, Inc. |
Method for treating bone fracture with anti-sclerostin antibodies
|
|
EP2231144B1
(en)
*
|
2007-12-24 |
2014-07-02 |
Sun Pharma Advanced Research Company Limited |
Nanodispersion
|
|
US8871276B2
(en)
|
2008-02-11 |
2014-10-28 |
Technion Research And Development Foundation Ltd. |
Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
|
|
US8865222B2
(en)
*
|
2008-02-11 |
2014-10-21 |
Technion Research And Development Foundation Ltd. |
Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
|
|
US8865223B2
(en)
*
|
2008-02-11 |
2014-10-21 |
Technion Research And Development Foundation Ltd. |
Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
|
|
EP2252269A1
(en)
*
|
2008-02-11 |
2010-11-24 |
Technion Research and Development Foundation, Ltd. |
Casein particles encapsulating therapeutically active agents and uses thereof
|
|
CA2715422A1
(en)
*
|
2008-03-21 |
2009-09-24 |
Elan Pharma International Limited |
Compositions for site-specific delivery of imatinib and methods of use
|
|
EP2990487A1
(en)
|
2008-05-08 |
2016-03-02 |
Asuragen, INC. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
|
WO2010005725A2
(en)
*
|
2008-06-16 |
2010-01-14 |
Bind Biosciences, Inc. |
Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
|
|
JP5756751B2
(ja)
|
2008-06-26 |
2015-07-29 |
エータイアー ファーマ， インコーポレイテッド |
非正準的な生物学的活性を有するグリシル−ｔＲＮＡ合成酵素を含む組成物および方法
|
|
WO2010009075A1
(en)
*
|
2008-07-14 |
2010-01-21 |
The University Of North Carolina At Chapel Hill |
Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds
|
|
US20110190399A1
(en)
*
|
2008-07-31 |
2011-08-04 |
Santosh Kumar Kar |
Curcumin nanoparticles and methods of producing the same
|
|
CZ301005B6
(cs)
*
|
2008-08-29 |
2009-10-14 |
Fyzikální ústav AV CR, v.v.i. |
Zpusob prípravy hybridních nanocástic z aglomerátu nanocástic komplexních vícesložkových oxidu kovu
|
|
EP2326318A4
(en)
|
2008-09-16 |
2012-05-23 |
Univ Maryland |
SUR1 HEMMER FOR THERAPEUTIC PURPOSES
|
|
US20100099775A1
(en)
*
|
2008-10-17 |
2010-04-22 |
Alpharx Inc. |
Method for ameliorating of post-anesthetic recovery
|
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
|
US8765817B1
(en)
|
2008-12-03 |
2014-07-01 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
|
US8349899B1
(en)
|
2008-12-03 |
2013-01-08 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
|
SI2379096T1
(sl)
*
|
2008-12-19 |
2020-03-31 |
Baxalta GmbH |
Zaviralci TFPI in postopki uporabe
|
|
RU2391104C1
(ru)
*
|
2008-12-29 |
2010-06-10 |
Зоя Ивановна Микашинович |
Способ лечения фетоплацентарной недостаточности
|
|
EP2448406B1
(en)
|
2009-02-26 |
2016-04-20 |
Relmada Therapeutics, Inc. |
Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
|
|
US20120004185A1
(en)
|
2009-02-27 |
2012-01-05 |
Atyr Pharma, Inc. |
Polypeptide structural motifs associated with cell signaling activity
|
|
ES2638779T3
(es)
|
2009-03-16 |
2017-10-24 |
Pangu Biopharma Limited |
Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas
|
|
CN102449143B
(zh)
|
2009-03-31 |
2017-11-14 |
Atyr医药公司 |
包含具有非常规生物活性的天冬氨酰‑tRNA合成酶的组合物和方法
|
|
ES2702049T3
(es)
|
2009-04-24 |
2019-02-27 |
Univ Vanderbilt |
Inducción anti-TGF-beta de crecimiento óseo
|
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
|
WO2010138539A2
(en)
|
2009-05-27 |
2010-12-02 |
Elan Pharma International Ltd. |
Reduction of flake-like aggregation in nanoparticulate active agent compositions
|
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
CA2765541A1
(en)
|
2009-06-19 |
2010-12-23 |
Sun Pharma Advanced Research Company Ltd. |
Nanodispersion of a drug and process for its preparation
|
|
EP2451496B1
(en)
|
2009-07-10 |
2015-07-22 |
Boston Scientific Scimed, Inc. |
Use of nanocrystals for a drug delivery balloon
|
|
WO2011008737A2
(en)
|
2009-07-13 |
2011-01-20 |
The University Of North Carolina At Chapel Hill |
Engineered aerosol particles, and associated methods
|
|
WO2011011781A1
(en)
|
2009-07-24 |
2011-01-27 |
Baylor College Of Medicine |
Methods of modulation of branched chain acids and uses thereof
|
|
EP2477499B1
(en)
|
2009-09-14 |
2018-04-11 |
SillaJen Biotherapeutics, Inc. |
Oncolytic vaccinia virus combination cancer therapy
|
|
MX365946B
(es)
|
2009-12-10 |
2019-06-19 |
Turnstone Lp |
Rabdovirus oncolitico.
|
|
CN106474462A
(zh)
|
2009-12-11 |
2017-03-08 |
Atyr 医药公司 |
用于调节炎症的氨酰tRNA合成酶
|
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
|
WO2011075636A2
(en)
|
2009-12-18 |
2011-06-23 |
Amgen Inc. |
Wise binding agents and epitopes
|
|
US8932600B2
(en)
|
2010-01-27 |
2015-01-13 |
Glaxosmithkline Biologicals S.A. |
Modified tuberculosis antigens
|
|
TWI438009B
(zh)
*
|
2010-02-19 |
2014-05-21 |
Teikoku Pharma Usa Inc |
紫杉烷前－乳劑調配物及其製造與使用之方法
|
|
CA2793465C
(en)
|
2010-03-19 |
2022-06-14 |
Baxter International Inc. |
Tfpi inhibitors and methods of use
|
|
US9272053B2
(en)
|
2010-04-23 |
2016-03-01 |
University Of Massachusetts |
AAV-based treatment of cholesterol-related disorders
|
|
EP3540055A1
(en)
|
2010-04-23 |
2019-09-18 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
AU2011242527B2
(en)
|
2010-04-23 |
2016-05-19 |
University Of Florida Research Foundation, Inc. |
rAAV-guanylate cyclase compositions and methods for treating Leber's congenital amaurosis-1 (LCA1)
|
|
WO2011139714A2
(en)
|
2010-04-26 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
|
AU2011248614B2
(en)
|
2010-04-27 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
|
US9068177B2
(en)
|
2010-04-29 |
2015-06-30 |
Atyr Pharma, Inc |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
|
|
CA2797393C
(en)
|
2010-04-29 |
2020-03-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
|
JP6008838B2
(ja)
|
2010-04-29 |
2016-10-19 |
エータイアー ファーマ， インコーポレイテッド |
アスパラギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
MX341082B
(es)
|
2010-05-03 |
2016-08-08 |
Teikoku Pharma Usa Inc |
Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
|
|
EP2566496B1
(en)
|
2010-05-03 |
2018-02-28 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
|
JP5976638B2
(ja)
|
2010-05-03 |
2016-08-23 |
エータイアー ファーマ， インコーポレイテッド |
アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
WO2011140132A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
|
|
AU2011248101B2
(en)
|
2010-05-04 |
2016-10-20 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
|
|
US8945541B2
(en)
|
2010-05-14 |
2015-02-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
|
SMT202000095T1
(it)
|
2010-05-14 |
2020-03-13 |
Amgen Inc |
Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
|
|
WO2011146410A2
(en)
|
2010-05-17 |
2011-11-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
|
|
US8962560B2
(en)
|
2010-06-01 |
2015-02-24 |
Atyr Pharma Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
|
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
|
EP3192880B1
(en)
|
2010-08-18 |
2019-10-09 |
Fred Hutchinson Cancer Research Center |
Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
|
|
WO2012027611A2
(en)
|
2010-08-25 |
2012-03-01 |
Atyr Pharma, Inc. |
INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
|
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
|
US20120114688A1
(en)
|
2010-11-08 |
2012-05-10 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
|
KR101942237B1
(ko)
|
2011-01-04 |
2019-01-25 |
신라젠(주) |
종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
|
|
KR20140038358A
(ko)
|
2011-01-11 |
2014-03-28 |
페이트 세러퓨틱스, 인코포레이티드 |
신규의 Wnt 조성물 및 이러한 조성물의 치료학적 용도
|
|
WO2012103328A1
(en)
|
2011-01-26 |
2012-08-02 |
The Methodist Hospital Research Institute |
Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use
|
|
CN105969773A
(zh)
|
2011-02-03 |
2016-09-28 |
米尔纳医疗股份有限公司 |
Mir-124的合成模拟物
|
|
JP2014506791A
(ja)
|
2011-02-03 |
2014-03-20 |
マーナ セラピューティクス インコーポレイテッド |
ｍｉＲ−３４の合成模倣体
|
|
JP2014505714A
(ja)
|
2011-02-17 |
2014-03-06 |
エフ．ホフマン−ラ ロシュ アーゲー |
ホットメルト押出法による過冷却液体状態からの活性医薬成分の制御された結晶化方法
|
|
US9133272B2
(en)
|
2011-03-01 |
2015-09-15 |
Amgen Inc. |
Bispecific binding agents
|
|
AU2012236962B2
(en)
|
2011-03-25 |
2017-05-11 |
Amgen Inc. |
Anti-sclerostin antibody crystals and formulations thereof
|
|
RS60835B1
(sr)
|
2011-04-19 |
2020-10-30 |
Amgen Inc |
Metoda za lečenje osteoporoze
|
|
CA2840175C
(en)
|
2011-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
|
|
EP2717884A1
(en)
|
2011-06-06 |
2014-04-16 |
Chevron Phillips Chemical Company LP |
Use of metallocene compounds for cancer treatment
|
|
WO2012167382A1
(en)
|
2011-06-08 |
2012-12-13 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
|
CN103717240A
(zh)
|
2011-06-10 |
2014-04-09 |
蓝鸟生物公司 |
用于肾上腺脑白质营养不良症和肾上腺脊髓神经病的基因治疗载体
|
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
|
EP2734634B1
(en)
|
2011-07-22 |
2019-08-21 |
The University of Chicago |
Igf-1 for use in the treatment of migraine
|
|
ES2667554T3
(es)
|
2011-08-04 |
2018-05-11 |
Amgen Inc. |
Método para el tratamiento de los defectos de espacio óseo
|
|
US9655905B2
(en)
|
2011-09-14 |
2017-05-23 |
King Abdullah University Of Science And Technology |
Treatment of sickle cell disease
|
|
EP2758519B1
(en)
|
2011-09-21 |
2017-03-29 |
King Abdullah University Of Science And Technology |
Didemnin biosynthetic gene cluster in tistrella mobilis
|
|
BR112014007029A2
(pt)
|
2011-09-23 |
2017-04-11 |
Bluebird Bio Inc |
métodos aperfeiçoados de terapia gênica
|
|
WO2013095736A2
(en)
|
2011-09-27 |
2013-06-27 |
The Methodist Hospital Research Institute |
Gold-in-silicon nanoassembly for thermal therapy and methods of use
|
|
AU2012315699B2
(en)
|
2011-09-30 |
2017-08-17 |
Bluebird Bio, Inc. |
Compounds for improved viral transduction
|
|
CN104136026B
(zh)
|
2011-10-31 |
2018-03-02 |
卫理公会医院研究所 |
包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物
|
|
ES2687954T3
(es)
|
2011-11-11 |
2018-10-30 |
Fred Hutchinson Cancer Research Center |
Inmunoterapia de linfocitos T dirigidos a ciclina A1 contra el cáncer
|
|
US9562015B2
(en)
|
2011-11-17 |
2017-02-07 |
The Regents Of The University Of Colorado, A Body |
Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
|
|
US20130177627A1
(en)
*
|
2011-11-18 |
2013-07-11 |
Linda Einbond |
Growth inhibitory effects of nanoparticles containing triterpene glycosides or triterpenes
|
|
US9546367B2
(en)
|
2011-12-07 |
2017-01-17 |
Jenny Chee Ning Chang |
siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
|
|
AU2012362898B2
(en)
|
2011-12-28 |
2017-11-09 |
Amgen, Inc. |
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
|
|
CA2863083C
(en)
|
2012-01-26 |
2023-09-19 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
|
AU2013221448B2
(en)
|
2012-02-16 |
2017-02-23 |
The University Of Toledo |
Xenoantigen-displaying anti-cancer vaccines and method of making
|
|
NZ724133A
(en)
|
2012-03-21 |
2020-07-31 |
Baxalta Inc |
Tfpi inhibitors and methods of use
|
|
US20140128431A1
(en)
|
2012-04-03 |
2014-05-08 |
Hoffmann-Laroche Inc. |
Pharmaceutical composition with improved bioavailability, safety and tolerability
|
|
AR092821A1
(es)
|
2012-04-20 |
2015-05-06 |
Sucampo Ag |
Conjugado de derivado de acido graso-polimero
|
|
BR112014027834A2
(pt)
|
2012-05-23 |
2017-08-08 |
Univ Ohio State |
composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso
|
|
US9925260B2
(en)
|
2012-07-05 |
2018-03-27 |
Ucb Pharma S.A. |
Treatment for bone diseases
|
|
WO2014039189A1
(en)
|
2012-08-01 |
2014-03-13 |
Mcnally Elizabeth |
Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
|
|
PT2879701T
(pt)
|
2012-08-03 |
2024-02-12 |
Access To Advanced Health Inst |
Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
|
|
WO2014039908A1
(en)
|
2012-09-07 |
2014-03-13 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for regenerating hair cells and/or supporting cells
|
|
JO3685B1
(ar)
|
2012-10-01 |
2020-08-27 |
Teikoku Pharma Usa Inc |
صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
BR112015015758B1
(pt)
|
2013-01-22 |
2022-01-04 |
F. Hoffmann-La Roche Ag |
Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida
|
|
MX2015009901A
(es)
|
2013-02-01 |
2016-04-06 |
Santa Maria Biotherapeutics Inc |
Administración de un compuesto de antiactivina a a un sujeto.
|
|
CN105658790A
(zh)
|
2013-02-21 |
2016-06-08 |
东安大略研究所儿童医院有限公司 |
疫苗组合物
|
|
US10208012B2
(en)
|
2013-03-13 |
2019-02-19 |
Board Of Regents, The University Of Texas System |
Compounds for treating inflammatory and hyperproliferative diseases
|
|
TW201521769A
(zh)
|
2013-03-15 |
2015-06-16 |
Durect Corp |
具有流變改質劑以減少溶解變異性之組成物
|
|
ES2728865T3
(es)
|
2013-03-28 |
2019-10-29 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
|
|
US9393202B2
(en)
*
|
2013-04-26 |
2016-07-19 |
Chiesi Farmaceutici S.P.A |
Particle size reduction of an antimuscarinic compound
|
|
US10006049B2
(en)
|
2013-05-16 |
2018-06-26 |
University Of Florida Research Foundation, Incorporated |
Hairpin mRNA elements and methods for the regulation of protein translation
|
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
|
US10328127B2
(en)
|
2013-12-02 |
2019-06-25 |
Baylor College Of Medicine |
Methods for stimulation of appetite and increase in weight by administration of asprosin
|
|
CA2942101A1
(en)
|
2014-03-21 |
2015-09-24 |
Abbvie Inc. |
Anti-egfr antibodies and antibody drug conjugates
|
|
EP3129015B1
(en)
|
2014-04-08 |
2021-07-14 |
The Methodist Hospital |
Inos-inhibitory compositions and their use as breast cancer therapeutics
|
|
WO2015157500A1
(en)
|
2014-04-09 |
2015-10-15 |
Research Development Foundation |
Class iia hdac inhibitors for the treatment of infection
|
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
EP3157953B1
(en)
|
2014-06-20 |
2021-12-22 |
Aveo Pharmaceuticals, Inc. |
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
|
|
US20170137505A1
(en)
|
2014-06-20 |
2017-05-18 |
Aveo Pharmaceuticals, Inc. |
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
|
|
US10278986B2
(en)
|
2014-08-14 |
2019-05-07 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibody-siRNA conjugates and uses therefor
|
|
US10414809B2
(en)
|
2014-09-01 |
2019-09-17 |
Academia Sinica |
Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
|
|
CA2960209C
(en)
|
2014-09-04 |
2023-08-29 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
|
US20170306008A1
(en)
|
2014-09-25 |
2017-10-26 |
Aveo Pharmaceuticals, Inc. |
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|
|
JP6842410B2
(ja)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
新規の高効率ライブラリーにより同定されるａａｖベクター
|
|
RU2738421C2
(ru)
|
2014-10-21 |
2020-12-14 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
US10302644B2
(en)
|
2014-11-04 |
2019-05-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
|
EP3233131A1
(en)
|
2014-12-16 |
2017-10-25 |
Board of Regents of the University of Nebraska |
Gene therapy for juvenile batten disease
|
|
US10166197B2
(en)
|
2015-02-13 |
2019-01-01 |
St. John's University |
Sugar ester nanoparticle stabilizers
|
|
WO2016145217A1
(en)
|
2015-03-10 |
2016-09-15 |
The Trustees Of Columbia University In The City Of New York |
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
|
|
US11285190B2
(en)
|
2015-04-20 |
2022-03-29 |
The Board Of Regents Of The University Of Texas System |
CLEC11a is a bone growth agent
|
|
US11020443B2
(en)
|
2015-04-23 |
2021-06-01 |
University Of Massachusetts |
Modulation of AAV vector transgene expression
|
|
US10011629B2
(en)
|
2015-05-01 |
2018-07-03 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
|
WO2016183292A1
(en)
|
2015-05-14 |
2016-11-17 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
|
CA3026452C
(en)
|
2015-06-04 |
2023-03-21 |
Crititech, Inc. |
Nozzle assembly and methods for use
|
|
WO2016205615A1
(en)
|
2015-06-17 |
2016-12-22 |
The Johns Hopkins University |
Tdp-43 in degenerative disease
|
|
RU2018113280A
(ru)
|
2015-09-16 |
2019-10-16 |
ДиЭфБи СОРИА, ЭлЭлСи |
Доставка наночастиц лекарственного средства и способы их использования
|
|
EP3357396B1
(en)
*
|
2015-09-28 |
2019-11-06 |
Sumitomo Osaka Cement Co., Ltd. |
Method for manufacturing dishwasher/dryer
|
|
EA036155B1
(ru)
|
2015-10-16 |
2020-10-06 |
Маринус Фармасьютикалс, Инк. |
Инъекционные составы нейростероида, содержащие наночастицы
|
|
DK3364997T5
(da)
|
2015-10-22 |
2024-09-30 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
|
WO2017079746A2
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
BR112018015390A2
(pt)
|
2016-01-27 |
2018-12-18 |
Oncorus, Inc. |
vetores virais oncolíticos e usos dos mesmos
|
|
US10695322B2
(en)
|
2016-01-29 |
2020-06-30 |
The Johns Hopkins University |
Inhibitors of bacterial growth
|
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
WO2017143112A2
(en)
|
2016-02-17 |
2017-08-24 |
The Johns Hopkins University |
An oxazolidinone for treatment of infections with mycobacterium tuberculosis
|
|
WO2017147215A1
(en)
|
2016-02-22 |
2017-08-31 |
The Methodist Hospital |
Biomimetic proteolipid vesicle compositions and uses thereof
|
|
WO2017147370A1
(en)
|
2016-02-24 |
2017-08-31 |
The Johns Hopkins University |
Novel antiviral proteins and their uses in therapeutic methods
|
|
CA3016457A1
(en)
|
2016-03-02 |
2017-09-08 |
The Board Of Regents Of The University Of Texas System |
Sting activating nanovaccine for immunotherapy
|
|
CN115287301A
(zh)
|
2016-03-03 |
2022-11-04 |
马萨诸塞大学 |
用于非病毒基因转移的末端封闭型线性双链体dna
|
|
US10888549B2
(en)
|
2016-03-07 |
2021-01-12 |
The Johns Hopkins University |
Pharmaceutical agents targeting cancer stem cells
|
|
US11965009B2
(en)
|
2016-03-10 |
2024-04-23 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
|
US11203626B2
(en)
|
2016-03-10 |
2021-12-21 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
|
MX2018010850A
(es)
|
2016-03-10 |
2019-05-15 |
Univ Johns Hopkins |
Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
|
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
KR102889062B1
(ko)
|
2016-03-17 |
2025-11-21 |
더 존스 홉킨스 유니버시티 |
Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
|
|
WO2017173055A1
(en)
|
2016-03-30 |
2017-10-05 |
The Johns Hopkins University |
Olfr90 specificity and methods of detection
|
|
SG11201808125RA
(en)
|
2016-04-04 |
2018-10-30 |
Crititech Inc |
Methods for solid tumor treatment
|
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
|
JP2019521095A
(ja)
|
2016-05-21 |
2019-07-25 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
|
|
BR112018075649A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
|
|
EP3468598A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
JP2019522643A
(ja)
|
2016-06-08 |
2019-08-15 |
アッヴィ・インコーポレイテッド |
抗ｃｄ９８抗体及び抗体薬物コンジュゲート
|
|
IL300274A
(en)
|
2016-06-08 |
2023-04-01 |
Abbvie Inc |
Antibodies against B7–H3 and conjugates of drug and antibody
|
|
EP3468993A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
MX2019000221A
(es)
|
2016-07-05 |
2020-02-07 |
Univ Massachusetts |
Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma.
|
|
MY205229A
(en)
|
2016-07-06 |
2024-10-08 |
Durect Corp |
Oral dosage form with drug composition, barrier layer and drug layer
|
|
KR102546501B1
(ko)
|
2016-07-19 |
2023-06-21 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
Stat3를 타겟으로 하는 종양용해성 바이러스
|
|
MX2019001669A
(es)
|
2016-08-11 |
2019-09-27 |
Ovid Therapeutics Inc |
Metodos y composiciones para el tratamiento de trastornos epilepticos.
|
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
|
US11801290B2
(en)
|
2016-09-16 |
2023-10-31 |
Access To Advanced Health Institute |
Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
US11149275B2
(en)
|
2016-10-10 |
2021-10-19 |
The Johns Hopkins University |
Device and method to treat esophageal disorders
|
|
US11578340B2
(en)
|
2016-10-13 |
2023-02-14 |
University Of Massachusetts |
AAV capsid designs
|
|
EP3538553A4
(en)
|
2016-11-08 |
2020-11-25 |
University of Miami |
ANTI-SECRETOGRANIN III (SCG3) ANTIBODIES AND THEIR USES
|
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
|
US10434089B2
(en)
|
2017-01-25 |
2019-10-08 |
The Johns Hopkins University |
Avibactam and carbapenems antibacterial agents
|
|
SG11201906744VA
(en)
|
2017-01-27 |
2019-08-27 |
Methodist Hospital |
Core/shell structure platform for immunotherapy
|
|
KR20190128050A
(ko)
|
2017-02-03 |
2019-11-14 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
종양용해성 바이러스 요법
|
|
EP3579824A1
(en)
|
2017-02-12 |
2019-12-18 |
Ben-Gurion University Of The Negev Research And Development Authority |
Telomerase activating compounds for use in fertility and related applications
|
|
WO2018170172A1
(en)
|
2017-03-14 |
2018-09-20 |
Baylor College Of Medicine |
Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
|
|
EP3595633B1
(en)
|
2017-03-15 |
2023-07-05 |
DFB Soria, LLC |
Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
|
|
EP3606544B1
(en)
|
2017-04-05 |
2025-06-04 |
University of Massachusetts |
Minigene therapy
|
|
KR20200003160A
(ko)
|
2017-05-03 |
2020-01-08 |
바이오마린 파머수티컬 인크. |
조혈모세포의 형질도입을 위한 개선된 렌티바이러스
|
|
AU2018281145A1
(en)
|
2017-06-06 |
2020-01-02 |
University Of Massachusetts |
Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome
|
|
SG11201909840TA
(en)
|
2017-06-09 |
2019-11-28 |
Crititech Inc |
Treatment of epithelial cysts by intracystic injection of antineoplastic particles
|
|
WO2018231908A1
(en)
|
2017-06-14 |
2018-12-20 |
Crititech, Inc. |
Methods for treating lung disorders
|
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
|
WO2019023483A1
(en)
|
2017-07-26 |
2019-01-31 |
Oncorus, Inc. |
ONCOLYTIC VIRAL VECTORS AND USES THEREOF
|
|
WO2019028469A1
(en)
|
2017-08-04 |
2019-02-07 |
The Methodist Hospital |
FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE
|
|
AU2018330165B2
(en)
|
2017-09-08 |
2025-07-17 |
Access To Advanced Health Institute |
Liposomal formulations comprising saponin and methods of use
|
|
KR20200064112A
(ko)
|
2017-10-03 |
2020-06-05 |
크리티테크, 인크. |
암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
|
|
US20200330541A1
(en)
|
2017-11-16 |
2020-10-22 |
University Of Maine System Board Of Trustees |
Compositions and methods for modulating endothelial cell migration and angiogenesis
|
|
AU2018378683B2
(en)
|
2017-12-06 |
2025-10-09 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
|
EP4137578A1
(en)
|
2018-01-05 |
2023-02-22 |
Ottawa Hospital Research Institute |
Modified vaccinia vectors
|
|
WO2019173478A2
(en)
|
2018-03-06 |
2019-09-12 |
The Johns Hopkins University |
Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
|
|
JP7372252B2
(ja)
|
2018-03-16 |
2023-10-31 |
ディーエフビー ソリア リミテッド ライアビリティ カンパニー |
タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法
|
|
WO2020036635A2
(en)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
|
KR20200135433A
(ko)
|
2018-03-23 |
2020-12-02 |
유니버시티 오브 매사추세츠 |
골 장애 치료를 위한 유전자 치료제
|
|
CN119241705A
(zh)
|
2018-03-30 |
2025-01-03 |
安姆根有限公司 |
C末端抗体变体
|
|
US12054724B2
(en)
|
2018-04-10 |
2024-08-06 |
President And Fellows Of Harvard College |
AAV vectors encoding clarin-1 or GJB2 and uses thereof
|
|
US11472848B2
(en)
|
2018-04-27 |
2022-10-18 |
University Of Massachusetts |
AAV capsids identified by in vivo library selection
|
|
CA3098871A1
(en)
|
2018-05-08 |
2019-11-14 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
|
WO2020028222A1
(en)
|
2018-07-29 |
2020-02-06 |
Musc Foundation For Research Development |
Compounds for the treatment of neurological or mitochondrial diseases
|
|
WO2020033130A1
(en)
|
2018-08-06 |
2020-02-13 |
The Johns Hopkins University |
Treatment of irritable bowel syndrome with molybdenum
|
|
US12103968B2
(en)
|
2018-08-16 |
2024-10-01 |
The Johns Hopkins University |
Antibodies to human ZnT8
|
|
AU2019347666B2
(en)
|
2018-09-28 |
2025-10-02 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
|
US12274733B2
(en)
|
2018-09-28 |
2025-04-15 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
|
CA3113470A1
(en)
|
2018-09-28 |
2020-04-02 |
President And Fellows Of Harvard College |
Mutant reverse tetracycline transactivators for expression of genes
|
|
AU2019358806B2
(en)
|
2018-10-08 |
2025-06-05 |
Allen Institute |
Artificial expression constructs for selectively modulating gene expression in interneurons
|
|
US12391947B2
(en)
|
2018-11-29 |
2025-08-19 |
University Of Massachusetts |
Modulation of SPTLC1 via recombinant adeno-associated vectors
|
|
WO2020115283A1
(en)
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Bispecific antibodies binding factor ixa and factor x
|
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
|
WO2020114615A1
(en)
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Bispecific antibodies binding factor ixa and factor x
|
|
AU2019406214A1
(en)
|
2018-12-21 |
2021-08-05 |
Northwestern University |
Use of annexins in preventing and treating muscle membrane injury
|
|
WO2020139977A1
(en)
|
2018-12-26 |
2020-07-02 |
Northwestern University |
Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
|
|
CN113557035B
(zh)
|
2019-01-12 |
2025-09-05 |
卫理公会医院 |
自组装肽纳米颗粒和其用途
|
|
WO2020163766A1
(en)
|
2019-02-07 |
2020-08-13 |
Baylor College Of Medicine |
Periosteal skeletal stem cells in bone repair
|
|
US20220054655A1
(en)
|
2019-02-22 |
2022-02-24 |
University Of Massachusetts |
Oxr1 gene therapy
|
|
AU2020228028A1
(en)
|
2019-02-25 |
2021-09-30 |
University Of Massachusetts |
DNA-binding domain transactivators and uses thereof
|
|
WO2020219990A1
(en)
|
2019-04-26 |
2020-10-29 |
President And Fellows Of Harvard College |
Aav vectors encoding mini-pcdh15 and uses thereof
|
|
US11717506B2
(en)
|
2019-05-07 |
2023-08-08 |
The Johns Hopkins University |
Neuroprotective compounds for amyotrophic lateral sclerosis
|
|
WO2020234448A1
(en)
*
|
2019-05-23 |
2020-11-26 |
Helm Ag |
Nanoparticles comprising enzalutamide
|
|
EA202193251A1
(ru)
|
2019-06-05 |
2022-03-10 |
Эмори Юниверсити |
Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
|
|
EP4009982A4
(en)
|
2019-08-05 |
2023-08-09 |
Marinus Pharmaceuticals, Inc. |
GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
|
|
CN114555814A
(zh)
|
2019-09-13 |
2022-05-27 |
罗特格斯新泽西州立大学 |
Aav相容的层粘连蛋白-连接子聚合蛋白
|
|
US12366570B2
(en)
|
2019-10-01 |
2025-07-22 |
The Johns Hopkins University |
Cell-based ZNT8 assay
|
|
US20220380735A1
(en)
|
2019-10-10 |
2022-12-01 |
Oncorus, Inc. |
Dual viruses and dual oncolytic viruses and methods of treatment
|
|
WO2021076656A1
(en)
|
2019-10-15 |
2021-04-22 |
University Of Massachusetts |
Rna editor-enhanced rna trans-splicing
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
MX2022006014A
(es)
|
2019-12-06 |
2022-06-22 |
Marinus Pharmaceuticals Inc |
Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
|
|
EP4081227A4
(en)
|
2019-12-26 |
2023-11-29 |
Figene, LLC |
Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
|
|
EP4081222A4
(en)
|
2019-12-26 |
2023-11-01 |
Figene, LLC |
PREVENTION AND TREATMENT OF KIDNEY FAILURE BY ADMINISTRATION OF FIBROBLASTS AND PRODUCTS THEREOF
|
|
CA3167217A1
(en)
|
2020-01-13 |
2021-07-22 |
Durect Corporation |
Sustained release drug delivery systems with reduced impurities and related methods
|
|
CA3165713A1
(en)
|
2020-01-30 |
2021-08-05 |
Andrew Scharenberg |
Bispecific transduction enhancer
|
|
US12485166B2
(en)
|
2020-02-06 |
2025-12-02 |
Longhorn Vaccines And Diagnostics, Llc |
Vaccines for the treatment and prevention of zoonotic infections
|
|
EP4110931A4
(en)
|
2020-02-25 |
2024-03-27 |
University of Massachusetts |
Inducible single aav system and uses thereof
|
|
IL296166A
(en)
|
2020-03-04 |
2022-11-01 |
Pleopharma L L C |
Methods and preparations for treating cannabis use disorder and facilitating cannabinoid withdrawal
|
|
AU2021248577A1
(en)
|
2020-03-31 |
2022-09-29 |
Sichuan Univeristy |
AAV capsids variants and uses thereof
|
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
|
AU2021284465A1
(en)
|
2020-06-04 |
2023-02-02 |
Allen Institute |
Artificial expression constructs for selectively modulating gene expression in inhibitory neocortical neurons
|
|
US20230287038A1
(en)
|
2020-08-07 |
2023-09-14 |
Access To Advanced Health Institute |
Purified saponins and chromatographic process for purification of same
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
KR20230091978A
(ko)
|
2020-10-20 |
2023-06-23 |
롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 |
면역원성 항원
|
|
US20230383359A1
(en)
|
2020-10-23 |
2023-11-30 |
Mirati Therapeutics, Inc. |
Methods for treatment of lung cancers
|
|
KR20230117177A
(ko)
|
2020-12-03 |
2023-08-07 |
유니버시티 오브 매사추세츠 |
진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발
|
|
KR20220082558A
(ko)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
|
|
CN116940358A
(zh)
|
2021-01-12 |
2023-10-24 |
度勒科特公司 |
持续释放药物递送系统和有关的方法
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
EP4281559A4
(en)
|
2021-01-22 |
2024-12-04 |
University of Massachusetts |
Use of novel mirna-binding site cassettes for antigen-presenting cell detargeting of transgene expression by raav gene therapy vectors
|
|
AU2022212952A1
(en)
|
2021-01-27 |
2023-08-10 |
Umoja Biopharma, Inc. |
Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
|
|
JP2024515974A
(ja)
|
2021-04-26 |
2024-04-11 |
ユニバーシティ オブ マサチューセッツ |
シュタルガルト病（ａｂｃａ４）の遺伝子治療
|
|
EP4433098A1
(en)
|
2021-11-18 |
2024-09-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
|
US20250011812A1
(en)
|
2021-11-23 |
2025-01-09 |
University Of Massachusetts |
Gene therapy for spinal muscular atrophy
|
|
GB2614309A
(en)
|
2021-12-24 |
2023-07-05 |
Stratosvir Ltd |
Improved vaccinia virus vectors
|
|
CA3248645A1
(en)
|
2022-01-28 |
2023-08-03 |
Fundacio Centre De Regulacio Genomica |
THERAPEUTIC CYTOKINES AND METHODS
|
|
JP2025511883A
(ja)
|
2022-04-06 |
2025-04-16 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
中枢神経系の加齢を逆行させること
|
|
EP4525899A1
(en)
|
2022-05-17 |
2025-03-26 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
IL318505A
(en)
|
2022-08-09 |
2025-03-01 |
Hunan Lonstar Biotech Co Ltd |
Metal-phospholipid complex, metal-phospholipid complex particle, drug-lipid particle, method for preparing same, and use thereof
|
|
JP2025527207A
(ja)
|
2022-08-09 |
2025-08-20 |
湖南長星生物医藥有限公司 |
金属－ポリフェノール複合体粒子、薬物－脂質粒子、並びにその製造方法及び応用
|
|
CN120882864A
(zh)
|
2022-09-30 |
2025-10-31 |
国立大学法人 东京大学 |
靶向il13ra2的单纯疱疹病毒及抗il13ra2抗体或其抗原结合片段
|
|
WO2024097992A2
(en)
|
2022-11-04 |
2024-05-10 |
Umoja Biopharma, Inc. |
Particles displaying adhesion-molecule fusions
|
|
WO2024130212A1
(en)
|
2022-12-16 |
2024-06-20 |
Turnstone Biologics Corp. |
Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
|
|
WO2024238153A1
(en)
|
2023-05-15 |
2024-11-21 |
Umoja Biopharma, Inc. |
Lentiviral delivery of anti-cd20 chimeric antigen receptors
|
|
WO2025231174A1
(en)
|
2024-04-30 |
2025-11-06 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2025235604A1
(en)
|
2024-05-08 |
2025-11-13 |
Umoja Biopharma, Inc. |
Fusion protein for use as immune cell engager
|
|
US12171841B1
(en)
|
2024-07-19 |
2024-12-24 |
Imam Mohammad Ibn Saud Islamic University |
Synthesis and characterization of glauconite-based silicate nanorods as anticancer agent
|